

► differences between fields. “Take a group of smart biologists and put them in a room of smart computer scientists and they will talk two different languages to each other, and have different mindsets,” says Daphne Koller, chief computing officer at Calico — a biotechnology company in San Francisco, California, that is backed by Google’s parent, Alphabet.

Scientists also had to identify which types of study could be conducted using networks that must be trained with huge sets of images before they can start making predictions. When Google wanted to use deep learning to find mutations in genomes, its scientists had to convert strands of DNA letters into images that computers could recognize. Then they trained their network on DNA snippets that had been aligned with a reference genome, and whose mutations were known. The end result was DeepVariant, a tool released in December that can find small variations in DNA sequences. In tests, DeepVariant performed at least as well as conventional tools.

Cell biologists at the Allen Institute for Cell Science in Seattle, Washington, are using convolutional neural networks to convert flat, grey

images of cells captured with light microscopes into 3D images in which some of a cell’s organelles are labelled in colour. The approach eliminates the need to stain cells — a process that requires more time and a sophisticated lab, and can damage the cell. Last month, the group published details of an advanced technique that can predict the shape and location of even more cell parts using just a few pieces of data — such as the cell’s outline (G. R. Johnson *et al.* Preprint at bioRxiv <http://doi.org/chwv>; 2017).

“What you’re seeing now is an unprecedented shift in how well machine learning can accomplish biological tasks that have to do with imaging,” says Anne Carpenter, director of the Imaging Platform at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. In 2015, her interdisciplinary team began to process cell images using convolutional neural networks; now, Carpenter says, the networks process about 15% of image data at her centre. She predicts that the approach will become the centre’s main mode of processing in a few years.

Others are most excited by the idea that analysing images with convolutional neural networks could inadvertently reveal subtle

biological phenomena, prompting biologists to ask questions they might not have considered before. “The most interesting phrase in science isn’t ‘Eureka!’, but ‘That’s weird — what’s going on?’” Nelson says.

Such serendipitous discoveries could help to advance disease research, says Rick Horwitz, the Allen Institute’s executive director. If deep learning can reveal subtle markers of cancer in an individual cell, he says, it could help to improve how researchers classify tumour progression. That could in turn trigger new hypotheses about how cancer spreads.

Other machine-learning connoisseurs in biology have set their sights on new frontiers, now that convolutional neural networks are taking flight for image processing. “Imaging is important, but so is chemistry and molecular data,” says Alex Wolf, a computational biologist at the German Research Center for Environmental Health in Neuherberg. Wolf hopes to tweak neural networks so that they can analyse gene expression. “I think there will be a very big breakthrough in the next few years,” he says, “that allows biologists to apply neural networks much more broadly.” ■

FUNDING

Facebook billionaire pours funds into high-risk research

Silicon Valley philanthropy project revives some grants rejected by US government.

BY EWEN CALLAWAY

After his plan to test a cancer vaccine for middle-aged pet dogs was rejected by the US National Institutes of Health (NIH), inventor and biochemist Stephen Johnston sought funding outside the mainstream system. On 20 December, the Open Philanthropy Project, a grant-giving organization that is largely funded by Facebook co-founder Dustin Moskovitz and his wife, Cari Tuna, announced that Johnston will receive US\$6.4 million to test the vaccine he developed. His team at Arizona State University in Tempe is now poised to enrol its first pooches in a clinical trial.

The science-funding efforts of the Open Philanthropy Project, or Open Phil, have so far flown under the radar compared with those of other Silicon Valley funders. But that is likely to change. The organization, which was launched in 2011 but rebranded under its current name in 2014, has significantly boosted its spending to \$200 million this year, of which around \$40 million went to scientific

research. And Chris Somerville, a biochemist and a scientific adviser to the organization, says that Open Phil’s total spending will rise several times over the coming years.

Moskovitz, whose estimated net worth is more than \$14 billion, and Tuna have said that they plan to give away most of their fortune during their lifetimes. It is likely that,



Dogs with cancer are about to be enrolled in a clinical trial of a vaccine for the disease.

JOHN MOORE/GETTY